Adage Capital Partners
CPRX icon

Adage Capital Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

Adage Capital Partners’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40,000
Closed -$672K – 890
2023
Q4 		$672K Buy
+40,000
New +$547K ﹤0.01% 776

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Adage Capital Partners's CPRX Position: Q1 2024 in Review

Adage Capital Partners sold out of Catalyst Pharmaceutical (CPRX) in Q1 2024, closing a stake of 40,000 shares — an estimated $672K sold.

Adage Capital Partners first reported a position in CPRX in Q4 2023 and held it in 1 quarter. The position peaked at $672K in Q4 2023. 269 funds tracked by Wall St. Rank hold CPRX as of Q1 2024.

  • Adage Capital Partners reported no remaining Catalyst Pharmaceutical position as of Q1 2024 after selling out during the quarter.
  • Adage Capital Partners sold 40,000 Catalyst Pharmaceutical shares in Q1 2024, an estimated $672K.
  • Adage Capital Partners first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 1 quarter.
  • Adage Capital Partners's Catalyst Pharmaceutical position peaked at $672K in Q4 2023.
  • 269 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2024.

Based on Adage Capital Partners's 13F filing for Q1 2024, filed 15 May 2024.